Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | G596D |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | BRAF G596D lies within the protein kinase domain of the Braf protein (UniProt.org). G596D demonstrates decreased Braf kinase activity in one study (PMID: 28783719), but results in increased Erk phosphorylation in another study, and is associated with resistance to Raf inhibitors (PMID: 31158244), and therefore, its effect on Braf protein function is unknown. |
| Associated Drug Resistance | Y |
| Category Variants Paths |
BRAF mutant BRAF G596X BRAF G596D |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140753348C>T |
| cDNA | c.1787G>A |
| Protein | p.G596D |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004333.5 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_004333 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| XM_005250045 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_001378467.1 | chr7:g.140753357C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_001354609.1 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140753348C>T | c.1787G>A | p.G596D | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G596D | breast cancer | predicted - resistant | Dabrafenib | Preclinical | Actionable | In a preclinical study, Tafinlar (dabrafenib) treatment did not inhibit Erk phosphorylation in breast cancer cells expressing BRAF G596D in culture (PMID: 31158244). | 31158244 |